Log In Sign Up

Trading

Trading

Browse Companies

Data

Data

Private Market Index

IPO Stock Tracker

Solutions

Solutions

For Institutions

For Shareholders

Insights

Insights

Popular Topics

Buying Pre-IPO Shares

Selling Pre-IPO Shares

Private Market Reports

Private Market Data & Analytics

About

About

Investor Relations

People & Culture

OcuNexus Therapeutics Stock

ocunexus.comHealthcareFounded: 1900Funding to Date: $144.36MM

Ocunexus Therapeutics is a biotechnology company focused on inflammasome modulation for treatment of Dry Age-related Macular Degeneration and Diabetic Retinopathy.

Buy or sell OcuNexus Therapeutics stock Learn more about OcuNexus Therapeutics IPO

Overview Financings Valuation

Enterprise Value (based on primary financings)

Enterprise Value

View Enterprise Value for OcuNexus Therapeutics.

Register Today

Team

Management Team

David Pool

Chief Financial Officer

Bradford Duft JD

Co-Founder, President & Board Member

Brian Levy

Chief Executive Officer

Anthony Phillips Ph.D

Medical & Pre-Clinical Consultant

Tracey Sunderland

Chief Operating Officer

Colin Green Ph.D

Scientific Co-Founder & Advisor

David Becker Ph.D

Scientific Co-Founder

Board Members

Howard Greene

Geoffrey Brooke MD

GBS Venture Partners

Bradford Duft JD

Inna Eitan

RusnanoMedInvest

James Blair Ph.D

Domain Associates

James Mervis JD

Mikhail Getman Ph.D

RusnanoMedInvest

Rajiv Shukla

Frank Spurway

Other companies like OcuNexus Therapeutics in the Healthcare sector

Sector

Last Round Est. Valuation

$3.67B

Sector

Last Round Est. Valuation

$809.52MM

Colossal Biosciences

Sector

Last Round Est. Valuation

$1.01B

Sector

Sector

Last Round Est. Valuation

$4.26B

Sector

Sector

Last Round Est. Valuation

$396.01MM

Sector

Last Round Est. Valuation

$400.53MM

Sector

Last Round Est. Valuation

$1.53B

Frequently Asked Questions

Updated on: Jun 3, 2023